Trump Administration Picks 15 Drugs For Medicare Price Negotiations
CMS gives drugmakers until Feb. 28, 2026 to accept negotiations for 15 drugs that accounted for about $27 billion in Medicare spending.
Overview
Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz announced on Feb. 1, 2026 that the Trump Administration selected 15 drugs for Medicare price negotiations, including Trulicity, Biktarvy and Botox, and said negotiated prices will take effect in 2028, according to CMS.
The 15 drugs were used by roughly 1.8 million Medicare Part B or Part D enrollees over the past year and accounted for about 6% of combined Part B and Part D spending, representing about $27 billion in total spending, CMS said.
Dr. Mehmet Oz said in a Feb. 1 statement that under President Trump's leadership CMS will "negotiate fair prices" for the most expensive drugs to reduce costs for seniors and taxpayers, according to CMS.
AARP CEO Dr. Myechia Minter-Jordan called the announcement "a significant step forward" in a statement, while PhRMA Executive Vice President Elizabeth Carpenter said the Inflation Reduction Act "continues to show why government price setting is the wrong approach," according to their statements.
Drugmakers have until Feb. 28, 2026 to decide whether to participate in the negotiations, and CMS said prices agreed through the program will be implemented in 2028 with the Type 2 diabetes drug Tradjenta slated for renegotiation under this round.
Analysis
Center-leaning sources present this coverage neutrally: factual lede, balanced inclusion of an administration statement and industry criticism, and context about prior negotiation rounds and affected drugs. Loaded terms (e.g., 'skyrocketing') appear only in attributed quotes, while reporting itself avoids evaluative language and omits partisan framing or selective viewpoint suppression.